Compare Incyte Corporation (INCY) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ferrari NV — how do they compare? Incyte Corporation trades at $117.76 (market cap $23.11B), while Ferrari NV trades at $370.4 (market cap $65.48B). The key difference: Ferrari NV is far larger — about 2.8× Incyte Corporation's market cap, and Ferrari NV pays a 1.14% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RACE | |
|---|---|---|
Market Cap | $23.11B | $65.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $517.65 |
52-Week Low | $67.38 | $314.63 |
Enterprise Value | $19.13B | $66.69B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Ferrari (RACE) trades at $371.52, down 1.41% on the day, with a bullish technical signal from moving averages. The company exhibits strong fundamentals, including a 22.19% net income margin and consistent earnings beats, with Q2 2026 results due July 30, 2026. Recent news highlights institutional buying, a share buyback program, and the debut of its first electric vehicle, though the Luce model received mixed initial reception.
The outlook remains positive given analyst consensus, with a $467.50 price target implying significant upside. Key risks include execution on the EV transition and high valuation multiples. The stock presents a growth opportunity driven by brand strength and pricing power, but investors should weigh near-term volatility around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
